Barry Johnson Email & Phone Number

Englewood, Colorado, United States

Design & synthesis of Chromophores for high speed low power non-liner electro-optic modulators with an emphasis on silicon photonic integrated devises.

Synthetic medicinal chemist: Expertise designing, synthesizing, purifying and characterizing organic compounds for therapeutic targets. I am seeking new opportunities as a medicinal chemist to facilitate the discovery of new or better drug entities.

• Designed, synthesized, purified and characterized inhibitors of HIV LEDGF, HIV Integrace, HCV NS5B, HIV Attachment and HCV Protease.
• HIV LEDGF: Developed a novel core/chemistry with tether aromatic moieties reaching into a new binding pocket providing improved activity, idea based on modeling within an x-ray crystal structure
• HIV Integrace: Created an amine appendage on a tertiary carbon that provided improved solubility, maintained activity and reduced glucuronidation
• HCV… Show more Designed, synthesized, purified and characterized inhibitors of HIV LEDGF, HIV Integrace, HCV NS5B, HIV Attachment and HCV Protease.
• HCV NS5B: Generated a unique heterocyclic component that improved HURG and toxicity issues providing a compound which underwent advanced evaluation for clinical nomination
• HIV Attachment: Produced a creative urea moiety on a core that addressed solubility issues to get around the need for pro-drug derivatives and provided sub-nM activity

Wilmington, DE

• Syntheses aided development of Sustiva™ beyond a toxicity issue. Designed, fabricated, purified and characterized compounds as inhibitors of HIV NNRT (first & second generation) and HIV Protease.
• Enabled the advancement of Sustiva™ beyond a rodent toxicity impasse by synthesizing proposed rat metabolites
• Created and optimized a novel tricyclic azaacridine HIV NNRTI core that address activity against resistant viral strains o Azaacridine DPC-A78277 advanced into Phase I clinical… Show more Syntheses aided development of.
• Created and optimized a novel tricyclic azaacridine HIV NNRTI core that address activity against resistant viral strains o Azaacridine DPC-A78277 advanced into Phase I clinical trials DPC-A78277 had very favorable.
• HIV NNRT: Delineated the construction of 1-3 & 1-4-benzodiazapinones to overcome synthetic problems to produce novel first generation inhibitors
• HIV protease: Composed and fabricated P1/P1’ tethered heterocyclic moieties on a cyclic urea scaffold to address resistance issues and aqueous solubility Show less

Master Of Science (Ms), Organic Chemistry (Medicinal)

Prof. John F. W. Keana

Bachelor Of Science (Bs), Chemistry (Comprehensive)

Eau Claire branch, Prof. Leo A. Ochrymowycz